Visual Performance of Clareon Vivity and PureSee IOL
ConditionCataract
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50+
SponsorOMIQ Research
About this trial
This is study to determine the visual performance of patients with age-related cataracts implanted in both eyes with either of two extended depth of focus intraocular lenses, the Clareon Vivity (Alcon Healthcare) or the PureSee (Johnson \& Johnson)
Eligibility criteria
Qualifiers
Patients of any sex and race aged 50 years or older
Patients undergoing bilateral age-related cataract surgery with a lens opacity grade 3 or higher in the LOCS III grading scale
Willing to receive implantation of an EDOF IOL
Willing to sign the informed consent and attend the study visits
Disqualifiers
Requirement of a spherical or toric power of the IOL to achieve emmetropia beyond the available range of either of the two lenses
The number of patients included with low astigmatism that require an equivalent to a T2 toric IOL will be capped to 10 patients/group
Irregular astigmatism
Contact lens wear in the previous 3 weeks before biometry
Trial design
Treatments tested in this trial
- Phacoemulsification with implantation of an extended depth of focus intraocular lens
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov